N-苄氧羰基-3,6-二氢-2H-吡啶-4-硼酸频哪醇酯 | 286961-15-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苄氧羰基-3,6-二氢-2H-吡啶-4-硼酸频哪醇酯
• 中文别名: N-CBZ--1,2,5,6-四氢吡啶-4-硼酸频哪醇酯；3,6-二氢-4-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1(2H)-吡啶羧酸苯甲酯；3,6-二氢-2H-吡啶-1-N-Cbz-4-硼酸频呐醇酯
• 英文名称: benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate；benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate；4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester；N-benzyloxycarbonyl-3,6-dihydro-2H-pyridine-4-boronic acid pinacol ester；benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1 (2H)-pyridinecarboxylate；N-Cbz-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester
• CAS: 286961-15-7
• 化学式: C₁₉H₂₆BNO₄
• mdl: MFCD11521562
• 分子量: 343.231
• InChiKey: QDSFHRPYZPQWEJ-UHFFFAOYSA-N

物化性质

• 熔点：
  88-90℃
• 沸点：
  418.2±55.0 °C(Predicted)
• 密度：
  1.13

计算性质

• 辛醇/水分配系数(LogP)：
  3.59
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• TSCA：
  No
• 危险品标志：
  Xi
• 安全说明：
  S26,S37
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid, pinacol ester
Synonyms: Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid, pinacol ester
CAS number: 286961-15-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, under −20◦C.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C19H26BNO4
Molecular weight: 343.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于有机合成，也用作溶剂。

反应信息

• 作为反应物：
  描述：

  N-苄氧羰基-3,6-二氢-2H-吡啶-4-硼酸频哪醇酯 在 bis-triphenylphosphine-palladium(II) chloride 、 20% palladium hydroxide-activated charcoal 、 氢气 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 100.0 ℃ 、200.0 kPa 条件下， 反应 24.0h， 生成 4-(哌啶-4-基)苯甲酸
  参考文献：
  名称：

  [EN] BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS
  [FR] BENZO- ET PYRIDO-PYRAZOLES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE

  摘要：

  这项发明涉及公式（I）的新化合物，包含它们的药物组合物，以及它们用于药理治疗癌症，最好是胶质母细胞瘤的用途。

  公开号：

  WO2020212530A1
• 作为产物：
  描述：

  1-Cbz-4-哌啶酮 在 1,1'-双(二苯基膦)二茂铁 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 20.0h， 生成 N-苄氧羰基-3,6-二氢-2H-吡啶-4-硼酸频哪醇酯
  参考文献：
  名称：

  Discovery of 3-Methyl-N-(1-oxy-3‘,4‘,5‘,6‘-tetrahydro-2‘H-[2,4‘-bipyridine]-1‘-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D₄ Agonist for the Treatment of Erectile Dysfunction

  摘要：

  The goal of this study was to identify a structurally distinct D-4-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl) piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl) piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.

  DOI：

  10.1021/jm060662k
• 作为试剂：
  描述：

  联硼酸频那醇酯 、 potassium acetate 、 4-(三氟甲基磺酰氧基)-5,6-二氢吡啶-1(2H)-羧酸苄酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 1,1'-双(二苯基膦)二茂铁 N-苄氧羰基-3,6-二氢-2H-吡啶-4-硼酸频哪醇酯 、 二氯甲烷 、 Sodium sulfate-III 、 silica gel 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 16.0h， 以to provide the title compound (323 mg, 78% yield)的产率得到N-苄氧羰基-3,6-二氢-2H-吡啶-4-硼酸频哪醇酯
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式(I)1化合物治疗性功能障碍，以及含有式(I)化合物的组合物治疗性功能障碍。

  公开号：

  US20030229094A1

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Revolution Medicines, Inc.

  公开号：US20210139517A1

  公开（公告）日：2021-05-13

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• ATR抑制剂及其在医药上的应用
  申请人：贝达药业股份有限公司

  公开号：CN112851668A

  公开（公告）日：2021-05-28

  本发明涉及式(I)所示的一种新型化合物，其具有ATR调节活性。本发明还涉及这些化合物的制备方法以及包含其的药物组合物。
• Dibenzoxazepinone derivatives and uses thereof
  申请人：Harris New Ralph

  公开号：US20060154914A1

  公开（公告）日：2006-07-13

  Compounds of the Formula I: wherein m, n, k, A, X, Y, Z, Ar, R 1 , R 2 , R 3 , and R 4 are as defined herein. The compounds are useful as 5-HT6 receptor antagonists. Also provided are compositions comprising, methods of using, and methods of making the subject compounds.

  式I的化合物： 其中m、n、k、A、X、Y、Z、Ar、R1、R2、R3和R4如本文所定义。这些化合物可用作5-HT6受体拮抗剂。还提供了包含这些化合物的组合物、使用方法和制备这些化合物的方法。
• TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS
  申请人：Burger Matthew

  公开号：US20120225061A1

  公开（公告）日：2012-09-06

  The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

  本发明提供了一种公式(I)的化合物： 如本文所述，以及药用可接受的盐、对映异构体、旋转异构体、互变异构体或外消旋混合物。还提供了使用公式I的化合物治疗由PIM激酶介导的疾病或状况的方法，以及包含这些化合物的药物组合物。